Next generation Fc scaffold for multispecific antibodies

Summary: Bispecific antibodies (Bispecifics) demonstrate exceptional clinical potential to address some of the most complex diseases. However, Bispecific production in a single cell often requires the correct pairing of multiple polypeptide chains for desired assembly. This is a considerable hurdle...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Bram Estes, Athena Sudom, Danyang Gong, Douglas A. Whittington, Vivian Li, Christopher Mohr, Danqing Li, Timothy P. Riley, Stone D.-H. Shi, Jun Zhang, Fernando Garces, Zhulun Wang
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
Q
Acceso en línea:https://doaj.org/article/daec344ee874422b8d613ca7fb390ad7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:daec344ee874422b8d613ca7fb390ad7
record_format dspace
spelling oai:doaj.org-article:daec344ee874422b8d613ca7fb390ad72021-11-28T04:36:35ZNext generation Fc scaffold for multispecific antibodies2589-004210.1016/j.isci.2021.103447https://doaj.org/article/daec344ee874422b8d613ca7fb390ad72021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2589004221014188https://doaj.org/toc/2589-0042Summary: Bispecific antibodies (Bispecifics) demonstrate exceptional clinical potential to address some of the most complex diseases. However, Bispecific production in a single cell often requires the correct pairing of multiple polypeptide chains for desired assembly. This is a considerable hurdle that hinders the development of many immunoglobulin G (IgG)-like bispecific formats. Our approach focuses on the rational engineering of charged residues to facilitate the chain pairing of distinct heavy chains (HC). Here, we deploy structure-guided protein design to engineer charge pair mutations (CPMs) placed in the CH3-CH3′ interface of the fragment crystallizable (Fc) region of an antibody (Ab) to correctly steer heavy chain pairing. When used in combination with our stable effector functionless 2 (SEFL2.2) technology, we observed high pairing efficiency without significant losses in expression yields. Furthermore, we investigate the relationship between CPMs and the sequence diversity in the parental antibodies, proposing a rational strategy to deploy these engineering technologies.Bram EstesAthena SudomDanyang GongDouglas A. WhittingtonVivian LiChristopher MohrDanqing LiTimothy P. RileyStone D.-H. ShiJun ZhangFernando GarcesZhulun WangElsevierarticleBiochemistryBioengineeringBiomolecular engineeringStructural biologyScienceQENiScience, Vol 24, Iss 12, Pp 103447- (2021)
institution DOAJ
collection DOAJ
language EN
topic Biochemistry
Bioengineering
Biomolecular engineering
Structural biology
Science
Q
spellingShingle Biochemistry
Bioengineering
Biomolecular engineering
Structural biology
Science
Q
Bram Estes
Athena Sudom
Danyang Gong
Douglas A. Whittington
Vivian Li
Christopher Mohr
Danqing Li
Timothy P. Riley
Stone D.-H. Shi
Jun Zhang
Fernando Garces
Zhulun Wang
Next generation Fc scaffold for multispecific antibodies
description Summary: Bispecific antibodies (Bispecifics) demonstrate exceptional clinical potential to address some of the most complex diseases. However, Bispecific production in a single cell often requires the correct pairing of multiple polypeptide chains for desired assembly. This is a considerable hurdle that hinders the development of many immunoglobulin G (IgG)-like bispecific formats. Our approach focuses on the rational engineering of charged residues to facilitate the chain pairing of distinct heavy chains (HC). Here, we deploy structure-guided protein design to engineer charge pair mutations (CPMs) placed in the CH3-CH3′ interface of the fragment crystallizable (Fc) region of an antibody (Ab) to correctly steer heavy chain pairing. When used in combination with our stable effector functionless 2 (SEFL2.2) technology, we observed high pairing efficiency without significant losses in expression yields. Furthermore, we investigate the relationship between CPMs and the sequence diversity in the parental antibodies, proposing a rational strategy to deploy these engineering technologies.
format article
author Bram Estes
Athena Sudom
Danyang Gong
Douglas A. Whittington
Vivian Li
Christopher Mohr
Danqing Li
Timothy P. Riley
Stone D.-H. Shi
Jun Zhang
Fernando Garces
Zhulun Wang
author_facet Bram Estes
Athena Sudom
Danyang Gong
Douglas A. Whittington
Vivian Li
Christopher Mohr
Danqing Li
Timothy P. Riley
Stone D.-H. Shi
Jun Zhang
Fernando Garces
Zhulun Wang
author_sort Bram Estes
title Next generation Fc scaffold for multispecific antibodies
title_short Next generation Fc scaffold for multispecific antibodies
title_full Next generation Fc scaffold for multispecific antibodies
title_fullStr Next generation Fc scaffold for multispecific antibodies
title_full_unstemmed Next generation Fc scaffold for multispecific antibodies
title_sort next generation fc scaffold for multispecific antibodies
publisher Elsevier
publishDate 2021
url https://doaj.org/article/daec344ee874422b8d613ca7fb390ad7
work_keys_str_mv AT bramestes nextgenerationfcscaffoldformultispecificantibodies
AT athenasudom nextgenerationfcscaffoldformultispecificantibodies
AT danyanggong nextgenerationfcscaffoldformultispecificantibodies
AT douglasawhittington nextgenerationfcscaffoldformultispecificantibodies
AT vivianli nextgenerationfcscaffoldformultispecificantibodies
AT christophermohr nextgenerationfcscaffoldformultispecificantibodies
AT danqingli nextgenerationfcscaffoldformultispecificantibodies
AT timothypriley nextgenerationfcscaffoldformultispecificantibodies
AT stonedhshi nextgenerationfcscaffoldformultispecificantibodies
AT junzhang nextgenerationfcscaffoldformultispecificantibodies
AT fernandogarces nextgenerationfcscaffoldformultispecificantibodies
AT zhulunwang nextgenerationfcscaffoldformultispecificantibodies
_version_ 1718408287974588416